• Upma Sharma

      President

      Upma Sharma is President of Arsenal Medical. She has led the ResQFoam program from concept to the clinic, including management of the product development process, establishment of GMP contract manufacturing, and receipt of a FDA IDE approval. Previously, at Lyra Therapeutics, Upma advanced the company’s innovative drug delivery depot from concept through a Phase I clinical study. Under Upma’s leadership, Arsenal Medical and Lyra Therapeutics have been awarded more than $50M in government funding to support product development efforts. Upma earned a Ph.D. from Princeton University in Chemical Engineering and a B.S.E. with Honors from Purdue University. During a post-doctoral fellowship in Bioengineering at Rice University, Upma was awarded a NIH Training Grant in Nanobiology. Upma has authored more than 20 peer-reviewed scientific publications and is an inventor on more than 40 issued or pending patents worldwide, including 20 US issued patents.

      Upma Sharma is President of Arsenal Medical. She has led the ResQFoam program from concept to the clinic, including management of the product development process, establishment of GMP contract manufacturing, and receipt of a FDA IDE approval. Previously, at Lyra Therapeutics, Upma advanced the company’s innovative drug delivery depot from concept through a Phase I clinical study. Under Upma’s leadership, Arsenal Medical and Lyra Therapeutics have been awarded more than $50M in government funding to support product development efforts. Upma earned a Ph.D. from Princeton University in Chemical Engineering and a B.S.E. with Honors from Purdue University. During a post-doctoral fellowship in Bioengineering at Rice University, Upma was awarded a NIH Training Grant in Nanobiology. Upma has authored more than 20 peer-reviewed scientific publications and is an inventor on more than 40 issued or pending patents worldwide, including 20 US issued patents.

    • Richard Johnson

      Chief Financial Officer

      Rich joined Arsenal Medical as Chief Financial Officer in January 2020.  He is responsible for the company’s financial functions including accounting, audit, treasury, and corporate finance. Rich brings 25 years of experience in financial management, business leadership, corporate strategy, mergers and acquisitions and operational integration. Prior to joining Arsenal Medical, Rich served as Chief Financial Officer for NWN Corporation and FusionStorm, information technology hardware resellers.  His other leadership positions include Senior Vice President and Chief Financial Officer for Lake Region Medical, a medical device contract manufacturer and senior-level accounting and finance positions at A123 Systems, GT Advanced Technologies, and Ocean Spray Cranberries. Rich holds a Bachelor of Science in Accountancy from Bentley University and an MBA from Southern New Hampshire University where he has been an adjunct professor.  Rich is a Massachusetts-licensed Certified Public Accountant.

      Rich joined Arsenal Medical as Chief Financial Officer in January 2020.  He is responsible for the company’s financial functions including accounting, audit, treasury, and corporate finance. Rich brings 25 years of experience in financial management, business leadership, corporate strategy, mergers and acquisitions and operational integration. Prior to joining Arsenal Medical, Rich served as Chief Financial Officer for NWN Corporation and FusionStorm, information technology hardware resellers.  His other leadership positions include Senior Vice President and Chief Financial Officer for Lake Region Medical, a medical device contract manufacturer and senior-level accounting and finance positions at A123 Systems, GT Advanced Technologies, and Ocean Spray Cranberries. Rich holds a Bachelor of Science in Accountancy from Bentley University and an MBA from Southern New Hampshire University where he has been an adjunct professor.  Rich is a Massachusetts-licensed Certified Public Accountant.

    • Lee Core

      Vice President of Research & Development

      Lee is the Vice President of Research & Development at Arsenal Medical. In this role, he is responsible for the developmental design of combination devices for clinical investigational use and beyond. Prior to joining the company, Lee has 10 years of worldwide commercialization experience for a variety of PMA/510k products such as heart assist pumps (ABIOMED), septal closure devices (NMT Medical), thrombectomy devices and transcatheter valves (Medtronic). Lee is an inventive problem solver on at least 20 issued U.S. patents. He has also been the program manager of two NHLBI SBIR programs totaling over $5M in funding. Lee holds a Bachelor of Science in Mechanical Engineering and a Masters in Biomedical Engineering from Worcester Polytechnic Institute and a Masters in Business Administration from Babson College.

      Lee is the Vice President of Research & Development at Arsenal Medical. In this role, he is responsible for the developmental design of combination devices for clinical investigational use and beyond. Prior to joining the company, Lee has 10 years of worldwide commercialization experience for a variety of PMA/510k products such as heart assist pumps (ABIOMED), septal closure devices (NMT Medical), thrombectomy devices and transcatheter valves (Medtronic). Lee is an inventive problem solver on at least 20 issued U.S. patents. He has also been the program manager of two NHLBI SBIR programs totaling over $5M in funding. Lee holds a Bachelor of Science in Mechanical Engineering and a Masters in Biomedical Engineering from Worcester Polytechnic Institute and a Masters in Business Administration from Babson College.

    • Barry Shaw

      Senior Director of Quality

      Barry has worked in the medical device and biotechnology/pharmaceutical industries for over 20 years in Quality Control and Quality Assurance roles. Prior to joining Arsenal Medical, Barry was at Boston Scientific where he was responsible for the development of the analytical quality system supporting the successful launch of Boston Scientific’s drug eluting stent. Additionally, Barry has had Quality leadership roles at several biotechnology and pharmaceutical companies including Creative Biomolecules, AIR (Alkermes), and Sepracor supporting the development of clinical and commercial product. Barry has extensive experience developing and implementing quality systems to support the manufacture and analytical characterization of clinical trial and commercial product. Barry has a Bachelor of Science in Biology from the University of Delaware.

      Barry has worked in the medical device and biotechnology/pharmaceutical industries for over 20 years in Quality Control and Quality Assurance roles. Prior to joining Arsenal Medical, Barry was at Boston Scientific where he was responsible for the development of the analytical quality system supporting the successful launch of Boston Scientific’s drug eluting stent. Additionally, Barry has had Quality leadership roles at several biotechnology and pharmaceutical companies including Creative Biomolecules, AIR (Alkermes), and Sepracor supporting the development of clinical and commercial product. Barry has extensive experience developing and implementing quality systems to support the manufacture and analytical characterization of clinical trial and commercial product. Barry has a Bachelor of Science in Biology from the University of Delaware.

    • Richard Mott

      Chairman

      Richard Mott is currently a principal in Walkabout Consulting LLC, a management consulting and private equity firm. Mr. Mott currently consults for Warburg Pincus as an Executive in Residence. Mr. Mott served as President and Chief Executive Officer and Director of Kyphon Inc., a NASDAQ-listed global medical device company focused on minimally invasive spinal therapies, through its acquisition by Medtronic, Inc. in late 2007. Prior to Kyphon, Mr. Mott held several executive positions, most recently as Chief Operating Officer at Wilson Greatbatch Technologies, Inc., a NYSE-listed medical technology company as well as executive operating roles within the Bristol-Myers Squibb Company. Mr. Mott is currently Executive Chairman of the Board of Directors of Microchips Biotech, Inc., a company based on micro reservoir technology incorporating long-term implantable drug delivery technologies; Chairman of the Board of Directors of Silk Road Medical, a company which uses surgical techniques to protect the brain from stroke risk during carotid artery stenting; Executive Chairman of the Board of Directors of Relievant Medsystems, a company using therapeutic nerve ablation for the treatment of chronic low back pain; and member of the Board of Directors of Treace Medical Concepts, a company focused on foot and ankle surgical products. Mr. Mott is a Director/Owner of VFD Technologies, a private equity firm that invests in, acquires and owns manufacturing businesses with unique technical capabilities that specialize in high performance materials.

      Richard Mott is currently a principal in Walkabout Consulting LLC, a management consulting and private equity firm. Mr. Mott currently consults for Warburg Pincus as an Executive in Residence. Mr. Mott served as President and Chief Executive Officer and Director of Kyphon Inc., a NASDAQ-listed global medical device company focused on minimally invasive spinal therapies, through its acquisition by Medtronic, Inc. in late 2007. Prior to Kyphon, Mr. Mott held several executive positions, most recently as Chief Operating Officer at Wilson Greatbatch Technologies, Inc., a NYSE-listed medical technology company as well as executive operating roles within the Bristol-Myers Squibb Company. Mr. Mott is currently Executive Chairman of the Board of Directors of Microchips Biotech, Inc., a company based on micro reservoir technology incorporating long-term implantable drug delivery technologies; Chairman of the Board of Directors of Silk Road Medical, a company which uses surgical techniques to protect the brain from stroke risk during carotid artery stenting; Executive Chairman of the Board of Directors of Relievant Medsystems, a company using therapeutic nerve ablation for the treatment of chronic low back pain; and member of the Board of Directors of Treace Medical Concepts, a company focused on foot and ankle surgical products. Mr. Mott is a Director/Owner of VFD Technologies, a private equity firm that invests in, acquires and owns manufacturing businesses with unique technical capabilities that specialize in high performance materials.

    • Upma Sharma, Ph.D.

      President, Arsenal Medical

      Upma Sharma is President of Arsenal Medical. She has led the ResQFoam program from concept to the clinic, including management of the product development process, establishment of GMP contract manufacturing, and receipt of a FDA IDE approval. Previously, at Lyra Therapeutics, Upma advanced the company’s innovative drug delivery depot from concept through a Phase I clinical study. Under Upma’s leadership, Arsenal Medical and Lyra Therapeutics have been awarded more than $50M in government funding to support product development efforts. Upma earned a Ph.D. from Princeton University in Chemical Engineering and a B.S.E. with Honors from Purdue University. During a post-doctoral fellowship in Bioengineering at Rice University, Upma was awarded a NIH Training Grant in Nanobiology. Upma has authored more than 20 peer-reviewed scientific publications and is an inventor on more than 40 issued or pending patents worldwide, including 20 US issued patents.

      Upma Sharma is President of Arsenal Medical. She has led the ResQFoam program from concept to the clinic, including management of the product development process, establishment of GMP contract manufacturing, and receipt of a FDA IDE approval. Previously, at Lyra Therapeutics, Upma advanced the company’s innovative drug delivery depot from concept through a Phase I clinical study. Under Upma’s leadership, Arsenal Medical and Lyra Therapeutics have been awarded more than $50M in government funding to support product development efforts. Upma earned a Ph.D. from Princeton University in Chemical Engineering and a B.S.E. with Honors from Purdue University. During a post-doctoral fellowship in Bioengineering at Rice University, Upma was awarded a NIH Training Grant in Nanobiology. Upma has authored more than 20 peer-reviewed scientific publications and is an inventor on more than 40 issued or pending patents worldwide, including 20 US issued patents.

    • Carmichael Roberts, Ph.D.

      Managing Partner, Material Impact, Arsenal Medical Co-Founder

      Dr. Carmichael Roberts co-founded Material Impact in 2016 where he builds and invests in early-stage companies that make products using unique chemistry and materials inventions. Prior to Material Impact, Carmichael was a partner at North Bridge Venture Partners and co-led the Series A investment in Arsenal Medical. Carmichael built his career as a serial entrepreneur before joining North Bridge. As an example, Carmichael served as the initial president and chief executive officer of Arsenal Medical. In 1999, Carmichael was named one of the world’s top 100 young entrepreneurs by MIT’s Technology Review. Prior to his entrepreneurial career, Carmichael worked in business development at GelTex Pharmaceuticals, which was acquired by Genzyme for $1.3 billion, and in new product and business development at Dow Chemical (formerly Union Carbide Corporation). Carmichael received his bachelor’s and doctorate degrees in organic chemistry from Duke University, and he completed his postdoctoral National Science Foundation fellowship at Harvard University. Carmichael also holds a master’s degree in business administration from the MIT Sloan School of Management. He serves on the Boards for the Massachusetts General Hospital Physicians Organization (MGPO), the Consumer Technology Association (CTA), WGBH and Duke University, including its Health System (DUHS). He is also a senior member of Breakthrough Energy, the $1B climate-focused fund started and chaired by Bill Gates

      Dr. Carmichael Roberts co-founded Material Impact in 2016 where he builds and invests in early-stage companies that make products using unique chemistry and materials inventions. Prior to Material Impact, Carmichael was a partner at North Bridge Venture Partners and co-led the Series A investment in Arsenal Medical. Carmichael built his career as a serial entrepreneur before joining North Bridge. As an example, Carmichael served as the initial president and chief executive officer of Arsenal Medical. In 1999, Carmichael was named one of the world’s top 100 young entrepreneurs by MIT’s Technology Review. Prior to his entrepreneurial career, Carmichael worked in business development at GelTex Pharmaceuticals, which was acquired by Genzyme for $1.3 billion, and in new product and business development at Dow Chemical (formerly Union Carbide Corporation). Carmichael received his bachelor’s and doctorate degrees in organic chemistry from Duke University, and he completed his postdoctoral National Science Foundation fellowship at Harvard University. Carmichael also holds a master’s degree in business administration from the MIT Sloan School of Management. He serves on the Boards for the Massachusetts General Hospital Physicians Organization (MGPO), the Consumer Technology Association (CTA), WGBH and Duke University, including its Health System (DUHS). He is also a senior member of Breakthrough Energy, the $1B climate-focused fund started and chaired by Bill Gates

    • Dennis Dougherty

      Intersouth Partners

      Since founding Intersouth in 1985, Dennis Dougherty has been active in all aspects of the venture investment process. He has served on dozens of boards of directors for both private and public companies. He is known for his experienced insight, consensus building and syndicate leadership. Dennis has invested in and worked with portfolio companies through several economic cycles and has served as interim CEO when necessary. He has long been active in the venture industry having served on the board of directors of the National Venture Capital Association, on the Steering Committee for the Kauffman Fellows Program and as a mentor for two classes of Kauffman Fellows. He also served on the Board of the NC State University Seed Fund and the Governor’s Biotechnology Steering Committee. He was a founder of the highly successful Council for Entrepreneurial Development (CED) and the Chair of its first Venture Conference. In 2005, Mr. Dougherty was named the Ernst & Young Entrepreneur of the Year for the Carolinas. Prior to founding Intersouth, Mr. Dougherty was an office managing partner and head of the high growth business practice for Touche Ross & Co. Before entering finance and accounting, he was in sales and marketing for petrochemicals and polymers. He holds a B.A. from Oklahoma City University, where he was named Distinguished Alumnus of the Year, and where he served on the Board of Trustees for 8 years.

      Since founding Intersouth in 1985, Dennis Dougherty has been active in all aspects of the venture investment process. He has served on dozens of boards of directors for both private and public companies. He is known for his experienced insight, consensus building and syndicate leadership. Dennis has invested in and worked with portfolio companies through several economic cycles and has served as interim CEO when necessary. He has long been active in the venture industry having served on the board of directors of the National Venture Capital Association, on the Steering Committee for the Kauffman Fellows Program and as a mentor for two classes of Kauffman Fellows. He also served on the Board of the NC State University Seed Fund and the Governor’s Biotechnology Steering Committee. He was a founder of the highly successful Council for Entrepreneurial Development (CED) and the Chair of its first Venture Conference. In 2005, Mr. Dougherty was named the Ernst & Young Entrepreneur of the Year for the Carolinas. Prior to founding Intersouth, Mr. Dougherty was an office managing partner and head of the high growth business practice for Touche Ross & Co. Before entering finance and accounting, he was in sales and marketing for petrochemicals and polymers. He holds a B.A. from Oklahoma City University, where he was named Distinguished Alumnus of the Year, and where he served on the Board of Trustees for 8 years.

    • George Whitesides, Ph.D.

      Woodford L. and Ann A. Flowers University Professor, Harvard University, Arsenal Medical Co-Founder

      Dr. Whitesides joined Harvard’s department of chemistry in 1982 and served as department chairman from 1986 to 1989. From 1963 to 1982, he was a faculty member at Massachusetts Institute of Technology. Dr. Whitesides held advisory positions on the National Research Council, National Science Foundation and the Department of Defense’s Defense Advanced Research Projects Agency (DARPA), and he is a member of the American Academy of Arts and Sciences, National Academy of Sciences, National Academy of Engineering and the American Philosophical Society, among other organizations. He has received dozens of honors, including the American Chemical Society (ACS) Award in Pure Chemistry (1975), the Arthur C. Cope Award (1995), the DARPA Award for Significant Technical Achievement (1996), the National Medal of Science (1998), the Von Hippel Award (2000), the Kyoto Prize (2003), the Dan David Award (2005), the Welch Award (2005), the Priestley Award (2007), the American Institute of Chemists Gold Medal (2007), the Prince of Asturias Foundation Award (2008), the Nanoscience Prize (2008), the Wheland Medal (2008) and the Benjamin Franklin Medal in Chemistry (2009). In addition to Arsenal Medical, George is a co-founder of a number of companies including Genzyme, GelTex, Theravance and 480 Biomedical. He received a Bachelor of Arts from Harvard University in 1960 and a doctorate from the California Institute of Technology in 1964.

      Dr. Whitesides joined Harvard’s department of chemistry in 1982 and served as department chairman from 1986 to 1989. From 1963 to 1982, he was a faculty member at Massachusetts Institute of Technology. Dr. Whitesides held advisory positions on the National Research Council, National Science Foundation and the Department of Defense’s Defense Advanced Research Projects Agency (DARPA), and he is a member of the American Academy of Arts and Sciences, National Academy of Sciences, National Academy of Engineering and the American Philosophical Society, among other organizations. He has received dozens of honors, including the American Chemical Society (ACS) Award in Pure Chemistry (1975), the Arthur C. Cope Award (1995), the DARPA Award for Significant Technical Achievement (1996), the National Medal of Science (1998), the Von Hippel Award (2000), the Kyoto Prize (2003), the Dan David Award (2005), the Welch Award (2005), the Priestley Award (2007), the American Institute of Chemists Gold Medal (2007), the Prince of Asturias Foundation Award (2008), the Nanoscience Prize (2008), the Wheland Medal (2008) and the Benjamin Franklin Medal in Chemistry (2009). In addition to Arsenal Medical, George is a co-founder of a number of companies including Genzyme, GelTex, Theravance and 480 Biomedical. He received a Bachelor of Arts from Harvard University in 1960 and a doctorate from the California Institute of Technology in 1964.

    • Richard D'Amore

      North Bridge Ventures

      Richard A. D’Amore has been a General Partner of North Bridge Venture Partners, an early-stage venture capital and growth equity firm, since co-founding the firm in 1994. Prior to starting North Bridge, Rich was a partner at Hambro International Equity Partners. Rich previously worked as a consultant at Bain and Company, and as a certified public accountant with Arthur Young and Company. Rich currently serves on a number of Boards of both public and private companies. Rich received a BS from Northeastern, summa cum laude, in 1976. He also has an MBA from Harvard University Graduate School of Business Administration where he was a Baker Scholar. A dedicated supporter of higher education, he is the Chairman of the Board of Trustees at Northeastern University, where he promotes innovation and research that drives economic growth.

      Richard A. D’Amore has been a General Partner of North Bridge Venture Partners, an early-stage venture capital and growth equity firm, since co-founding the firm in 1994. Prior to starting North Bridge, Rich was a partner at Hambro International Equity Partners. Rich previously worked as a consultant at Bain and Company, and as a certified public accountant with Arthur Young and Company. Rich currently serves on a number of Boards of both public and private companies. Rich received a BS from Northeastern, summa cum laude, in 1976. He also has an MBA from Harvard University Graduate School of Business Administration where he was a Baker Scholar. A dedicated supporter of higher education, he is the Chairman of the Board of Trustees at Northeastern University, where he promotes innovation and research that drives economic growth.

    • Robert Langer, D.Sc.

      David H. Koch Institute Professor, Massachusetts Institute of Technology, Arsenal Medical Co-Founder

      Robert S. Langer is one of 14 Institute Professors (the highest honor awarded to a faculty member) at the Massachusetts Institute of Technology (MIT). Dr. Langer has written approximately 1,130 articles. He also has approximately 800 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed more than 250 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history. He served as a member of the U.S. FDA’s SCIENCE Board, the agency’s highest advisory board, from 1995-2002, and as its chairman from 1999-2002. Dr. Langer has received more than 200 major awards including the 2006 United States National Medal of Science; the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers; and the 2008 Millennium Prize, the world’s largest technology prize. He is the only engineer to receive the Gairdner Foundation International Award; 76 recipients of this award have subsequently received a Nobel Prize. Among his multiple accolades, Forbes Magazine selected Dr. Langer as "one of the 15 innovators worldwide who will reinvent our future."

      Robert S. Langer is one of 14 Institute Professors (the highest honor awarded to a faculty member) at the Massachusetts Institute of Technology (MIT). Dr. Langer has written approximately 1,130 articles. He also has approximately 800 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed more than 250 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history. He served as a member of the U.S. FDA’s SCIENCE Board, the agency’s highest advisory board, from 1995-2002, and as its chairman from 1999-2002. Dr. Langer has received more than 200 major awards including the 2006 United States National Medal of Science; the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers; and the 2008 Millennium Prize, the world’s largest technology prize. He is the only engineer to receive the Gairdner Foundation International Award; 76 recipients of this award have subsequently received a Nobel Prize. Among his multiple accolades, Forbes Magazine selected Dr. Langer as "one of the 15 innovators worldwide who will reinvent our future."

    • Terrance G. McGuire

      Co-Founder and General Partner, Polaris Venture Partners

      Terry McGuire is a co-founder and general partner of Polaris Venture Partners based in the Boston office. Mr. McGuire focuses on life sciences investments. Prior to starting Polaris, Mr. McGuire spent seven years at Burr, Egan, Deleage & Co. investing in early-stage medical and information technology companies. Mr. McGuire has co-founded three companies: Inspire Pharmaceuticals, AIR (Advanced Inhalation Research, Inc.) and MicroCHIPS. Mr. McGuire represents Polaris on the boards of directors of Acceleron Pharma, Adimab, Arsenal Medical, deCODE Genetics, Ironwood Pharmaceuticals, Life Line Screening, MicroCHIPS, Pulmatrix, SustainX Energy Storage Solutions and Trevena. He has also served on the boards of Akamai, Aspect Medical Systems, Cubist Pharmaceuticals, GlycoFi, Transform Pharmaceuticals and Remon Medical Technologies. Mr. McGuire is chairman emeritus of the National Venture Capital Association. He chairs the board of overseers of the Thayer School of Engineering at Dartmouth College, and serves on the boards of MIT’s David Koch Institute for Integrative Cancer Research and the Arthur Rock Center for Entrepreneurship at Harvard Business School. Mr. McGuire holds a master’s degree in business administration from Harvard Business School, a Master of Science in engineering from The Thayer School at Dartmouth College and a Bachelor of Science in physics and economics from Hobart College. Mr. McGuire is a recipient of the 2009 Massachusetts Society for Medical Research Award and the 2005 Albert Einstein Award for Outstanding Achievement in the Life Sciences.

      Terry McGuire is a co-founder and general partner of Polaris Venture Partners based in the Boston office. Mr. McGuire focuses on life sciences investments. Prior to starting Polaris, Mr. McGuire spent seven years at Burr, Egan, Deleage & Co. investing in early-stage medical and information technology companies. Mr. McGuire has co-founded three companies: Inspire Pharmaceuticals, AIR (Advanced Inhalation Research, Inc.) and MicroCHIPS. Mr. McGuire represents Polaris on the boards of directors of Acceleron Pharma, Adimab, Arsenal Medical, deCODE Genetics, Ironwood Pharmaceuticals, Life Line Screening, MicroCHIPS, Pulmatrix, SustainX Energy Storage Solutions and Trevena. He has also served on the boards of Akamai, Aspect Medical Systems, Cubist Pharmaceuticals, GlycoFi, Transform Pharmaceuticals and Remon Medical Technologies. Mr. McGuire is chairman emeritus of the National Venture Capital Association. He chairs the board of overseers of the Thayer School of Engineering at Dartmouth College, and serves on the boards of MIT’s David Koch Institute for Integrative Cancer Research and the Arthur Rock Center for Entrepreneurship at Harvard Business School. Mr. McGuire holds a master’s degree in business administration from Harvard Business School, a Master of Science in engineering from The Thayer School at Dartmouth College and a Bachelor of Science in physics and economics from Hobart College. Mr. McGuire is a recipient of the 2009 Massachusetts Society for Medical Research Award and the 2005 Albert Einstein Award for Outstanding Achievement in the Life Sciences.